BioSpace News Archive

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.65 per share of the company’s common stock for the second quarter of 2021.

ATI Physical Therapy, one of the nation’s largest providers of physical therapy services, announced the appointment of Ryan Wilson to Chief Commercial Officer.

WATS3D, an AI-powered diagnostic platform developed by CDx Diagnostics to identify precancerous and cancerous cells in the esophagus, is now considered a medically necessary service by BlueCross BlueShield of South Carolina.

Exogenesis nanoMesh™ LLC, a subsidiary of Exogenesis Corporation, announced today the completion of production validation and sterilization validation as an immediate prelude to commercialization of Exogenesis nanoMesh™.

The Infusion Therapy Standards of Practice have long been considered the authority on infusion practice, and for this technology to be endorsed by the INS represents a breakthrough in gravity infusion technology and viability.

First COVID-19 testing event launched by a partnership among Quest Diagnostics, Choose Healthy Life and United Way of New York City at Harlem’s historic Abyssinian Baptist Church

ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ernesto Salegio, PhD will join the Company as Vice President, Segment Leader Translational and Pre-Clinical Research as part of ClearPoint’s Biologics and Drug Delivery team on March 1, 2021

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the 2020 World Conference on Lung Cancer (WCLC) on Friday, Jan. 29 , at 8:00 p.m. ET .

– 37 Percent of Patients Treated with Mitapivat Achieved ≥33% Reduction in Transfusion Burden Compared to Individual Historical Transfusion Burden Standardized to 24 Weeks (1-Sided p=0.0002) – – 22 Percent of Patients Treated with Mitapivat Were Transfusion-Free During the 24-Week Fixed Dose Period – – Safety Profile Consistent with Previously Reported Data

Omnicell, Inc. announced that WVU Medicine has expanded their partnership with Omnicell through a 10-year, sole source agreement renewal, with plans to leverage the Company’s industry-leading medication inventory management platform to improve pharmacy supply chain management across the West Virginia-based health network.